Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:01 PM
Ignite Modification Date:
2025-12-24 @ 3:01 PM
NCT ID:
NCT04141059
Eligibility Criteria:
Inclusion Criteria:
* Men and women 35 years or more age.
* Fitzpatrick skin phototype II-IV.
* Signed informed consent.
Exclusion Criteria:
* Present intolerances and/or food allergies related to Oligopin®.
* Being pregnant or intending to become pregnant.
* Be in breastfeeding period.
* Be a smoker.
* Participate in or have participate in a clinical trial or nutritional intervention study in the last 30 days prior to inclusion in the study.
* Present some chronic gastrointestinal disease.
* Present some chronic disease with clinical manifestation.
* Receive or are planning to receive facial cosmetic procedures such as facial peel, dermabrasion, laser treatments within six months prior to start the study.
* Take supplements or multivitamin supplements or phytotherapeutic products that interfere with the treatment under study up to 30 days before the start of the study.
* Has or are planning to take acne treatments, photoaging treatments or topical prescription products indicated for improving the appearance or condition of skin within 30 days.
* Present any skin disease (e.g., atopic skin, eczema, neurodermatitis or psoriasis) or other dermatological disorders (e.g., scars, sunburn or moles).
* Intensive sun or artificial UV exposure (solarium) on the test area within 30 days prior to study start or planned during the study period.
* Being unable to follow the study guidelines.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
35 Years
Study:
NCT04141059
Study Brief:
Protocol Section:
NCT04141059